We have also previously shown that FAK-dependent modulation of PD-L2 contributes toward the enhanced anti-tumour efficacy of a FAK inhibitor in combination with an agonistic antibody targeting the T-cell co-stimulatory receptor OX40 [24]. The gene discussed is PDCD1LG2; the disease is neoplasm.